Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

Highest ASCVD risk at follow-up seen for those who remained in or transitioned into low exposure categories over one year ...

A powerful new lab-made opioid is moving through the illegal US drug supply, and federal officials warn it could keep spreading. The drug, called cychlorphine, may be up to 10 times stronger than ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

The new biosimilar offers an additional treatment option for patients with multiple myeloma, bone metastases, and giant cell tumors of the bone.

The oral ALK2 inhibitor significantly reduced mean total new heterotopic ossification volume at 24 weeks in patients aged 12 ...

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.

Betzaida Tejada-Vera, from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from all death certificates filed in the 50 states and the District of Columbia ...

FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.

Associations included higher prevalence of focal to bilateral tonic-clonic seizures in drug-resistant epilepsy ...